FDA Modeling Workshop - CVP, Nov2013

  • Upload
    cvphilo

  • View
    219

  • Download
    0

Embed Size (px)

Citation preview

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    1/24

    Carl VPhillipsPhDScientific Director, CASAA (Consumer Advocates for

    Smoke-free Alternatives Association)

    FDA Workshop, Modeling and Statistical Methods

    for the Regulatory Assessment of Tobacco Products6 December 2013

    The Need for Economics-Based

    Modeling for Tobacco Harm

    Reduction

    !

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    2/24

    #$%&'() *+,-.& +/ 0+1233+ 4&- 12&%32..5 +(.5 32.34.20-657+06-'32.& 2(, -$0-(, 72&0 08-(,& 96%& %& (+0 4&-/4. /+8 4(,-8&02(,%() 0+,25:& 0+1233+ 4&-

    +8 /+8 8-)4.20+85 8-;4%8-*-(0&

    06-)$*+/ 06- &5&0-*

    96- *-362(%&* ,8%=%() 0+1233+ 4&- %& ?-./28--3+(+*%3& @3+(&4*-8 78-/-8-(3- 2(, 36+%3-A

    B40.%(- +/ *2%( 28)4*-(0

    C

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    3/24

    D(0-87+.2'() E F2.34.2'() =&G H+,-.%()

    I+ &%*7.- 3+(&02(0& %( 06- ?+8., +/ 0+1233+ 4&-

    9+ *+,-. J+? +/ ?20-8 068+4)6 2 3++.%() &5&0-*> ?- 32(&%*7.%/5 +40 06- *-362(%&*& %(0+ 6%)6K.-=-. -;42'+(&

    2 LM ,-)8-- 1-(, %( 2 !N 3* 7%7- 2.?25& 62& 06- &2*- -O-30 +(?20-8 78-&&48-

    P40 0+1233+ 4&- 1-62=%+8 ,+-& (+0 8-&-*1.- 65,824.%3& @06+4)6 5+4 3+4., 1- /+8)%=-( /+8 06%(Q%() &+ %/ 5+4 R4&0 .++Q-,

    20 06- -$%&'() *+,-.&> ?6%36 12&%32..5 08-20 %0 2& &436A

    %( /2%8(-&&> ,-32,-& +/ (-28K&2*-(-&& 38-20-, 06- %..4&%+( +/3+(&02(35

    S

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    4/24

    D(0-87+.2'() E F2.34.2'() =&G H+,-.%()

    I+ &%*7.- 3+(&02(0& %( 06- ?+8., +/ 0+1233+ 4&-

    96-8- 28- (+ 765&%32. 3+(&02(0& %( &+3%2. &3%-(3-& #7%,-*%+.+)5 !N! 0-236-& 0620 7-+7.-> 7.23-> 2(, '*-

    *2T-8>

    0620 %&> 7+74.2'+(& =285 2(, 362()-> 2(, 064& -7%,-*%+.+)%3-&'*20-& 28- (-=-8 3+(&02(0&

    0+ &25 (+06%() +/ -('8-.5 ,%O-8-(0 78+,430 +7'+(&> ?%0682,%32..5 ,%O-8-(0 %*7230&

    L

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    5/24

    D(0-87+.2'() E F2.34.2'() =&G H+,-.%()

    U- 28- 085%() 0+ 78-,%30 /28 +40K+/K&2*7.-

    U- 28- %(0-8-&0-, %(,-".'#/&0 %*7230& +/ (+=-. 78+,430&2(, (-? -,432'+(2. -O+80& @-G)G> *28Q-'()A>

    %( 2 ?+8., 2.8-2,5 3628230-8%V-, 15 *2&&%=- (+=-.05 D0 %& %*7+&&%1.- 0+ R4&0 3202.+) ?620 32*- 1-/+8- 2(,

    78-,%30 2( %*7230 ?%06%( 06- 1+4(,& +/ 06+&-

    +1&-8=2'+(&

    06+&- +1&-8=2'+(& ,+ (+0 3+=-8 06- &723- ?- 28- %(0-8-&0-, %( I+8 %& %0 &4W3%-(0 0+ R4&0 4&- 6%)6K.-=-. 657+06-'32.&

    @-G)G> 2&&4*- XY +/ 06- 7+74.2'+( &?%036-& 0+ 06%&GGGGAM

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    6/24

    D(0-87+.2'() E F2.34.2'() =&G H+,-.%()

    P40 657+06-'32.& 28- 1-T-8 062( (2%=- -$0827+.2'+(& +/78-=%+4& 6%)6K.-=-. +1&-8=2'+(&> 02Q%() 8-&4.0&

    21+40 2 ,%O-8-(0 78+,430> %( 2 ,%O-8-(0 7+74.2'+(>

    4(,-8 ,%O-8-(0 3%834*&02(3-&>

    and assume this predicts a novel situation. -G)G> 2&&4*- 2 (+=-. 9Z[ 78+,430 %( CN!L ?%.. 7-8/+8* 06- &2*- 2&

    &(4& %( CNNL

    -G)G> 2&&4*- &*+Q%() 72T-8(& %( 06- -82 +/ 9Z[ 8-&-*1.- 06+&- /8+*,-32,-& 72&0

    \436 4&- +/ ,202 %& (+0 &3%-(3-> %0 %& &47-8&''+(G @]U- &2? X /+..+? ^ +(3- %( 06- 72&0> &+ ?- 3+(3.4,- 0620 %0 2.?25& 6277-(&>

    ,-&7%0- (+0 62=%() 2(5 (+'+( +/ ?65 0620 *%)60 1-G_A

    `

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    7/24

    H-362(%&*&> (+0 &47-8&''+(

    D*2)%(- 78-,%3'() 06- 082R-30+85 +/ 2 &20-..%0- 8+3Q-0 .24(36/8+* a+8-2 4&%() 06- 78-=2.-(0 *-06+,& +/ 0+1233+ 1-62=%+8

    *+,-.%()b

    ^+4 ?+4., 78-,%30 0620 %0 ?+4., 1- +O 06- 3+2&0 +/ c.+8%,20?+ *%(40-& 2d-8 .24(36

    a-5b +/ 3+48&-> ?- 32( 78-,%30 ?6-8- 06- 8+3Q-0 8-2..5 ?%.. 1- *-362(%&*& +/ 8+3Q-0 J%)60 28- 4(,-8&0++,> 140 %/ 06-5 ?-8- (+0> ?- 3+4., e)48- 06-* +40 /8+* c.+8%,2

    .24(36 ,202 '1 )" 2(". '3 34 2&."-(3%&. 3$" !"#$%&'(!

    f

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    8/24

    H-362(%&*&> (+0 &47-8&''+(

    H-362(%&*& g U620 324&-& 06- *+=%() 7280& %( 06- *+,-. 0+,+ ?620 06-5 ,+

    H-362(%&*& 28- 8-.2'=-.5 3+(&%&0-(0> ?6-8-2& +403+*-& =285?%.,.5 ,-7-(,%() +( 3%834*&02(3-&

    D( 06%& 32&-> 06- *-362(%&*& 28- 3+(&4*-878-/-8-(3-&> %(,%=%,42.&: 082,-+O&> %(,%=%,42.

    Q(+?.-,)-> &+3%2. /+83-&> &477.5 /230+8&> -03G

    h /-? &028'() 7+%(0& 0620 28- (-3-&&285 0+ 4(,-8&02(, %/ ?-28- 0+ 62=- 2(5 6+7- +/ *+,-.%() 3+(&4*-8 1-62=%+8GGGG

    i

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    9/24

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    10/24

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    11/24

    H2(5 4&-8& &?%036 78+,430&

    ?6-( 06-5 7-83-%=- 0620 2(

    2.0-8(2'=- 78+=%,-& 1-T-8 (-0

    1-(-e0&G

    !!

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    12/24

    H+8- )-(-82..5> 0+1233+

    3+(&4*-8& 28- 085%() 0+

    *2$%*%V- 06-%8 (-0 ?-./28->R4&0 .%Q- 06-5 ,+ ?%06 06-%8

    +06-8 3+(&4*7'+( 36+%3-&

    !C

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    13/24

    P2&%3 -3+(+*%3& +/ 0+1233+ 78+,430 36+%3-

    1-(-e0& +/ -236

    728'34.28 78+,430748362&- 78%3-&

    7-83-%=-, 6-2.06

    -O-30&

    78-/-8-(3-&

    78+,430

    Q(+?.-,)-

    233-702(3-E

    7+74.28%05-,432'+(

    GGG

    ,-3%&%+(&

    6-2.06

    -O-30&

    65&0-8-&%&%(,%=%,42.&: 082,-+O& 2*+() 06-&-

    !S

    78+,430

    ;42.%05

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    14/24

    #3+(+*%3& %& 06- *-362(%&*

    h30+8& -236 *2Q- 06-%8 +?( ,-3%&%+( 12&-, +( 06%& ?6%36 .28)-.5 /+83-& 4& %(0+ %0"&356%(". !4."7'&0@hPHA *-06+,&

    96%& *-362(%&* (--,& 0+ 7280 +/ 2(5 23042. *+,-. +/ ?620 %&6277-(%()

    ?%06+40 %0> 06- ]*+,-._ %& 4(.%Q-.5 0+ 1- *+8- 062( 2 *-8- 32.34.20+8 +/657+06-'32.&

    2(, %& (--,-, 0+ )+ +40K+/K&2*7.-

    h( -O-3'=- *+,-. (--,& 0+ 1- 21.- 0+ "8,7%'& +1&-8=-, 6%)6K.-=-. +403+*-& -G)G> ,-38-2&- %( &*+Q%() %( 06- .20- CN063-(0485k 8-3-(0 &?%036%() 0+ &(4& %(

    I+8?25k 64)- 277-2. +/ -K3%)28-T-& %( 7+74.2'+(& 0620 (-=-8 -*1823-, &(4&

    !L

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    15/24

    #3+(+*%3& %& 06- *-362(%&*

    P40 %0 0-..& 4& /28 *+8- 062( &%*7.- 8-=%-? +/ 72&0 6%)6K.-=-.+403+*-&

    06- 7282*-0-8& /8+* 0620 J+?36280 28- &'.. (+0 3+(&02(0&> 140 06-5 28-3.+&-8 -(+4)6 0+ 3+(&02(0 0+ 1- 4&-/4.

    06-5 082(&/-8 0+ 2(2.5&-& +/ (+=-. &%042'+(& @&%*%.28 0+ 06- 8+3Q-0.%d%() /8+* 2 (+=-. .24(36 &%0-A

    -G)G> 6+? *436 -O-30 *%)60 *2&&K3+**4(%32'+( 21+40 2 78+,430:&.+? 8%&Q 62=-l

    -G)G> ,+-& 2 8-2. 78+,430 ;42.%05 362()- 62=- *436 %*7230 ?%06+40 2&+3%2. 14VVl

    -G)G> ,+ ?- Q(+? -(+4)6 21+40 2 728'34.28 78+,430& ;42.%05 @277-2.A0+ -=-( 8+4)6.5 78-,%30 %0& %*7230&> +8 %& 06- 4(3-802%(05 78+/+4(,

    !M

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    16/24

    H[9< )4%,2(3- @2(, (+?> 27728-(0.5> \# 277.%32'+(&A32.. /+8,-".'#/4&( 21+40 ?620 ?%.. 6277-( 4(,-8 (+=-.

    3%834*&02(3-&

    h7280 /8+* 8-)4.2'+(> -=-85+(- %(=+.=-, %& %(0-8-&0-,%( *2Q%() 78-,%3'+(& 2(, %,-('/5%() Q-5 .-=-8& +/

    3+(08+.

    #=-( 657+06-'32. 32.34.20+8& 28- %(38-2&%().5 4&-.-&&1-324&- 06-5 /2%. 0+ ,-2. ?%06 06- (+=-.'-&

    U65 ,+ ?- (--, 06%&l

    !`

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    17/24

    923 )%'3> &+*- *%)60 2&Q> '(&:3 ,-"1"-""56%(".!4."7'&0 1%- 344 #4!,7'#%3".; .4"(&:3 '3 ,-4.2#" -"(273(

    3$%3 %-" 2(, 06+4)60K/8--

    06-+8-'32. *+,-.& 28- 2.*+&0 )4282(0--, 0+ 1- ?8+()G

    !f

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    18/24

    h.. ,202 %& %(0-878-0-, 068+4)6 06-+85G

    U- (--, 06- 8%)60 4(,-8.5%() 06-+85G

    96-+85

    B1&-8=2'+(& +/ 78-=%+4& 1-62=%+8m202

    982(&%'+( 78+121%.%'-& /+8

    ]&2*-_ 23'+(& &025 06- &2*-

    H-362(%&*&b

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    19/24

    #3+(+*%3& %& 06- *-362(%&*

    96%& %& (+0 0+ %*7.5 0620 0+1233+ 4&- 36+%3-& @+8 2(5 36+%3-&A28- 7-8/-30.5 82'+(2. 2(, +7'*%V%()

    H2R+8 %882'+(2.%'-& ?-8- 2.8-2,5 7280 +/ 06- 21+=- &Q-036 +/06- *-362(%&*> 2(, +06-8& 32( 1- 2,,-,

    P40 &028'() ?%06 -3+(+*%3& o 82'+(2.%05> =+.%'+(> 7-+7.-085%() 0+ 1- 62775 o %& *436 1-T-8 062( 2&&4*%() 0+1233+

    4&- %& 324&-, 15 ,-*+(%3 7+&&-&&%+(

    #*7%8%32. ,-728048-& /8+* 82'+(2.%05 &6+4., 1- %(3.4,-,> 1402& 2 &028'() 7+%(0> 0+1233+ 3+(&4*7'+( %& 12&%32..5 .%Q- +06-8

    3+(&4*7'+( 36+%3-&

    06%& %(3.4,-& 06- 36+%3- 0+ &?%036 0+ .+?K8%&Q 2.0-8(2'=-& o %0 %& (+0 23.%(%32. 76-(+*-(+( +8 ,+(- 20 06- 1-6-&0 +/ 2406+8%05

    !j

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    20/24

    #3+(+*%3& %& 06- *-362(%&*

    m-*+(%3 7+&&-&&%+( ,-&38%1-& 06- 9+1233+ F+(08+. (+'+( +/06- 4(,-8.5%() *-362(%&*&

    h.0-8(2'=-.5 @%/ 5+4 .%Q- p%)60 8206-8 062( m28Q *506+&A %0 %& 2]06-+85 +/ %**234.20- 324&2'+(_

    #%06-8 ?25> 3.2%*& 21+40 ?65 2 728'34.28 362()- ?%.. 62=- 2728'34.28 -O-30 28- 4&42..5 2 *2)%3 2&0-8%&Q> ?6-8- 06-8- %&

    (+ -$7.2(2'+( /+8 ?65 0620 *%)60 1-

    2(, 2& ?- ?+4., -$7-30> 06- 78-,%3'+(& 28- 4&42..5 ?8+() 06- +1=%+4& -$3-7'+( %& 8-&7+(&- 0+ 78%3- %(38-2&-&>

    ?6-8- 06-8- %& 2 023%0 3+(3-&&%+( 0620 06- -3+(+*%3 *+,-.

    %& 8%)60

    CN

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    21/24

    H%)60 &--* 0620 +(3- ?- 62=- &48=-%..2(3- @-G)G> 8-;4%8-,%(,4&085 7+&0K*28Q-0 *+(%0+8%()A> 06- *+,-. %& (+ .+()-8

    (--,-,G

    P40 *+&0.5 2.. ?- 32( ,+ ?%06 &48=-%..2(3- ,202 21&-(0 28-2.%&'3 *+,-. %& R4&0 -$0-(, 06- 08-(, .%(-&G

    #G)G> ?- 62=- ,202 21+40 827%,.5 233-.-82'() 4702Q- +/ -K3%)28-T-&> 140b

    %& 06%& .%(-28 +8 .+)%&'3 )8+?06l

    ?6-8- ?%.. %0 .-=-. +Ol

    6+? ?%.. %(08+,43'+( +/ (-? 9Z[ 78+,430& 362()- 06-)8+?06 /+8 2(5 3488-(0 320-)+85l

    H-362(%&*K12&-, *+,-.%() 2.&+ (--,-, /+8

    4&-/4. &48=-%..2(3-

    C!

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    22/24

    h /-? 8-&4.0& /8+* -3+(+*%3&K12&-,

    *+,-.%() @&%*7.- &02'3 *+,-. 2(, hPHA@&+885> D ,+(:0 62=- '*- 0+ 78-&-(0 ,-02%.& +8 ,-8%=2'+(&>

    140 5+4 32( e(, 06-* %( ?620 D 62=- 741.%&6-, 21+40 06%&A

    h=2%.21%.%05 +/ 2(, Q(+?.-,)- 21+40 .+?K8%&Q 2.0-8(2'=-& 0+3%)28-T-& ?%.. %(38-2&- 0+02. 0+1233+ 4&-> #"3"-'( ,%-'62(

    D0 ?%.. ,+ 06%& 15 %(38-2&%() 06- (-0 1-(-e0& /8+* 4&%()0+1233+ 15 ,82*2'32..5 .+?-8%() 06- 3+&0 Z5&0-8-&%& 2(, &+3%2. Q(+?.-,)-E233-7021%.%05 -O-30& 28- 64)- [%)60 (+?> %0 %& 2.. 21+40 06- ,%&-;4%.%18%4*

    CC

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    23/24

    h /-? 8-&4.0& /8+* -3+(+*%3&K12&-,

    *+,-.%() @&%*7.- &02'3 *+,-. 2(, hPHA

    H%(+8 =28%2'+(& %( 78+,430 ;42.%05> 3+(,%'+(&> -03G 32( .-2,0+ 64)- ,%O-8-(3-& %( 2,+7'+( +/ 2 728'34.28 36+%3-

    -K3%)28-T-& -$7.+,-,k F2*-. \'3Q& J+77-, -$%&'() &5&0-*& *+,-.& ,+ (+0 0-(, 0+ 78-,%30 -%06-8 +/ 06-&-

    +403+*-&

    964&> 06-8- %& (-3-&&28%.5 64)- 4(3-802%(05 %( 2(5 -&'*20-G 2(5+(- ?6+ 3.2%*& 78-3%&- 78-,%3'+(& %& ,-.4,-, +8 .5%() @+8 Q(+?& 2

    ?25 0+ )-0 8%36 2(, ?%.. (+0 1- &628%() 06-%8 8-&4.0&A

    P40 %0 %& 7+&&%1.- 0+ 2&&-&& ?6%36 =28%21.-& 38-20- 06- )8-20-&0

    4(3-802%(05 2(, ?620 %(/+8*2'+( 3+..27&-& %0

    F+*%() 0+ )8%7& ?%06 06%& 4(3-802%(05 ?%.. 1- 2 64)- 7280 +/06- 7+74.2'+( -O-30& %&&4-& /+8 2(5 8-)4.20+85 78+3-&&

    CS

  • 8/13/2019 FDA Modeling Workshop - CVP, Nov2013

    24/24

    h3Q(+?.-,)*-(0&> 8-.20-, 8-2,%()> 2(, 3+(0230

    96- 3+(0-(0 +/ 06%& 78-&-(02'+( %& 2406+8K%(%'20-, 2(, -('8-.5 *5 ?+8Q2(, =%-?&G D 277-28 0+,25 20 *5 +?( 1-6-&0G D 062(Q Ph9> q9D> 2(, Fh\hh

    /+8 &477+80 +( 06- .28)-8 8-.20-, 8-&-2836 78+R-30> 06+4)6 06- *20-8%2.

    78-&-(0-, 6-8- %& 2( 2(0-3-,-(0 0+ 0620 ?+8QG

    H5 72&0 2(, /4048- 7+&0& 21+40 06%& 28- 02))-,b6T7bEE-7K+.+)5G1.+)&7+0G3+*E&-2836E.21-.E9Z[YCN*+,-.%()

    U+8Q%() 727-8 +( 06- 12&%3 -3+(+*%3& +/ 9Z[b 6T7bEE6-2.067+.%35&36+.28&G+8)E&%0-&E6-2.067+.%35&36+.28&G+8)Ee.-&E

    ?MNr76%..%7&G7,/

    s%,-+ +/ /4.. 78-&-(02'+( +/ 06- e8&0 =-8&%+( +/ hPH +/ &+3%2. ,5(2*%3& +/-K3%)28-T- 2,+7'+(b 6T7bEE1%0G.5E3=7F%05Z-2.06

    t328.=76%..%7&> 376%..%7&t32&22G+8)